This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Resources

Real World Experience

with EYLEA® (aflibercept) 8 mg

Eye banner image

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).

 

Explore the real-world experiences of UK clinicians implementing EYLEA® (aflibercept) 8 mg, highlighting its potential to address unmet needs in the treatment of nAMD and DMO.

International Medical Retina Congress Highlights on EYLEA 8 mg

These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg and highlight key learnings and updates from recent congresses.

Connect with us!
If you find these videos helpful, we invite you to stay updated on the latest resources regarding EYLEA 8 mg, including highlights from international congresses. Click below to reach out to us or to register for our communications!

Contact us here

European Society of Retina Specialists (EURETINA) Congress | September 2025

 

In this 11-minute video,

Richard Gale
(Consultant Ophthalmologist, York and Scarborough Teaching Hospitals NHS Foundation Trust) presents the latest 6-month real-world results from the EYLEA 8 mg
SPECTRUM
study for
nAMD
 patients, as shared at EURETINA.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

In this 12-minute video,

Richard Gale
(Consultant Ophthalmologist, York and Scarborough Teaching Hospitals NHS Foundation Trust) presents the latest 6-month real-world results from the EYLEA 8 mg
SPECTRUM
study for
DMO
 patients, as shared at EURETINA.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

UK Audits of EYLEA 8 mg Treatment for Patients with nAMD

These three UK audit videos highlight the successful integration of EYLEA 8 mg within leading ophthalmology clinics and aim to support you in assessing the impact of EYLEA 8 mg on patient care and clinical practice.

Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust

 

In this video,

Serena Salvatore
presents the drying effects of EYLEA 8 mg from an audit conducted at Bristol Eye Hospital. The video discusses the results of treating 352 naïve patients with EYLEA 8 mg.

  • Duration: 8 minutes
  • Treatment-naïve patients
  • nAMD

Prescribing information for EYLEA® (aflibercept)

can be found here
.

Early real-world experiences with EYLEA 8 mg booklet

This downloadable booklet presents outcomes from UK case studies conducted at:

  • Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust
  • Newmedica Eye Health Clinic & Surgical Centre, Grimsby
  • Western Eye Hospital, Imperial College Healthcare NHS Trust
Access Here

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025
Ophthalmology Resources
Access useful, downloadable ophthalmology resources
PP-EYL-GB-2954, September 2025
Retinal Pioneers Programme
A source of on-demand, educational resources developed in collaboration with national and international thought leaders
PP-EYL-GB-2908, August 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-3012 | October 2025